Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC

Stock Information for Helix BioPharma Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Helix BioPharma Corp.

Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Helix BioPharma Responds to Market Activity
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM
Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025
Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.